The year 2017 was marked by steady progress in Intec’s development program of AP-CDLD for the treatment of Parkinson’s disease (PD). The drug is a co-formulation of widely used carbidopa and levodopa using the company’s proprietary accordion pill (AP) technology. The program is in Phase III with more than 300 (of 420) patients enrolled to date with full enrolment expected in H218.
22 Mar 2018
Intec Pharma - Phase III more than half the way there
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Intec Pharma - Phase III more than half the way there
Indaptus Therapeutics, Inc. (INDP:NAS) | 0 0 0.0%
- Published:
22 Mar 2018 -
Author:
Maxim Jacobs -
Pages:
6
The year 2017 was marked by steady progress in Intec’s development program of AP-CDLD for the treatment of Parkinson’s disease (PD). The drug is a co-formulation of widely used carbidopa and levodopa using the company’s proprietary accordion pill (AP) technology. The program is in Phase III with more than 300 (of 420) patients enrolled to date with full enrolment expected in H218.